health
Department:
Health
REPUBLIC OF SOUTH AFRICA

Reference: EDP17102024/01

Enquiries:
Contract queries:
Ms Marione Schonfelt
E-mail:
marione.schonfeldt@health.gov.za

Stock queries:
Ms Babalwa Melitafa
E-mail:
Babalwa.Melitafa@health.gov.za

Clinical queries:
Essential Drugs Programme
E-mail: SAEDP@health.gov.za

NOTICE: ULTRA-FAST-ACTING AND LONG-ACTING INSULIN ANALOGUE INTERIM ESSENTIAL MEDICINES LIST STATUS

As communicated in previous circulars: (1) Availability of Insulin Pen Sets dated 06 May 2024 and (2) Guidance on insulin switching insulin pen sets to insulin vials, and human insulin products to insulin analogue products; there have been significant challenges in accessing human insulin pen sets.

Insulin analogue pen sets are available on contract. To enable equitable access to insulin pens, the specifically awarded insulin analogue products on contract HP06-2024SVP (*see Table 1 below*) have been made essential medicines and added to the essential medicines list (EML) temporarily. This temporary update to the EML would assist provinces in the procurement of these insulin pens in the absence of human insulin products. The EML status for specific products outlined in Table 1 is valid until the end of contract HP06-2024SVP *i.e. 30 April 2027.*

The inclusion of insulin analogues (not product specific) in the Standard Treatment Guidelines and Essential Medicines List (STGs and EML) in the long-term is still being further considered by the National Essential Medicines List Committee, particularly in terms of cost and availability.

Table 1: Insulin Analogues awarded on National Contract


Contract	NSN	Medicine Pack short Description	Brand As Per Contract	Supplier Name	Price
HP06-2024SVP	222000179	Insulin, Analogue, Human, Long Acting; 100IU/ml; pen, prefilled; 3 ml	OPTISULIN SOLOSTAR 3.64 MG/ML INJ 3 ML x 5	Sanofi-Aventis SA (Pty) Ltd	R39.12
HP06-2024SVP	222000181	Insulin, Analogue, Human, Ultrafast-Acting; 100IU/ml; pen, prefilled; 3 ml	APIDRA SOLOSTAR 100 IU/ML INJ 3 ML x 5	Sanofi-Aventis SA (Pty) Ltd	R74.40

Please see Annexure A and Annexure B to help guide switching from human insulin pen sets to analogue insulin pen sets.

A supplementary tender is underway to try enable access to biphasic insulin analogues. Further details on availability and status of these products will be provided on finalisation of this process.

Provinces and Healthcare Facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees. Kindly share with all healthcare professionals and relevant stakeholders.

Kind regards,



MS KHADIJA JAMALOODIEN
CHIEF DIRECTOR: SECTOR-WIDE PROCUREMENT
DATE: 17 October 2024